| A Study of AMG 820 in Subjects With Advanced Solid Tumors (NCT01444404) | AmMax Bio, Inc. | 2008-03-31 |
| Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors (NCT00605618) | Bristol-Myers Squibb | 2008-03-01 |
| Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors (NCT00618735) | Biogen | 2008-02-01 |
| Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin (NCT00861328) | Traws Pharma, Inc. | 2008-02-01 |
| Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors (NCT00879684) | Pfizer | 2008-01-01 |
| Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors (NCT00591383) | Alaunos Therapeutics | 2008-01-01 |
| A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1) (NCT00546247) | Bristol-Myers Squibb | 2008-01-01 |
| Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas (NCT00592163) | Alaunos Therapeutics | 2007-12-01 |
| A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2) (NCT00550017) | Bristol-Myers Squibb | 2007-12-01 |
| A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors (NCT00557856) | Pfizer | 2007-11-01 |
| Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors (NCT01148628) | Southern Europe New Drug Organization | 2007-10-01 |
| An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors (NCT00524524) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2007-08-01 |
| Phase I Trial of PX-478 (NCT00522652) | Cascadian Therapeutics Inc. | 2007-08-01 |
| Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors (NCT00519662) | Sunesis Pharmaceuticals | 2007-08-01 |
| Study of Intermittent OSI-906 Dosing (NCT00514306) | Astellas Pharma Inc | 2007-07-05 |
| Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas (NCT00955292) | Cylene Pharmaceuticals | 2007-07-01 |
| Study of Continuous OSI-906 Dosing (NCT00514007) | Astellas Pharma Inc | 2007-06-18 |
| Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan (NCT00473616) | AstraZeneca | 2007-05-01 |
| A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors (NCT00487058) | Novartis | 2007-05-01 |
| A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02) (NCT00520390) | Enzon Pharmaceuticals, Inc. | 2007-05-01 |
| A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01) (NCT00520637) | Enzon Pharmaceuticals, Inc. | 2007-05-01 |
| A Study of ARRY-520 in Patients With Advanced Cancer (NCT00462358) | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2007-04-01 |
| A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors (NCT00879554) | Pfizer | 2007-02-01 |
| An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor (NCT00441610) | Novartis Pharmaceuticals | 2007-01-01 |
| A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer (NCT00620594) | Novartis Pharmaceuticals | 2006-12-21 |
| QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors (NCT00974896) | NantCell, Inc. | 2006-12-01 |
| Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001) (NCT00359671) | Merck Sharp & Dohme LLC | 2006-12-01 |
| A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002) (NCT00635778) | Merck Sharp & Dohme LLC | 2006-08-07 |
| Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer (NCT01491204) | Hanmi Pharmaceutical Company Limited | 2006-08-01 |
| Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors (NCT00426582) | Novartis Pharmaceuticals | 2006-08-01 |
| Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy (NCT00782002) | Eli Lilly and Company | 2006-07-01 |
| A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor. (NCT00410358) | Novartis Pharmaceuticals | 2006-06-01 |
| Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin (NCT00507585) | M.D. Anderson Cancer Center | 2006-06-01 |
| RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies (NCT00529438) | Biogen | 2006-04-30 |
| A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available (NCT00785941) | Eli Lilly and Company | 2006-04-01 |
| Phase 1 Study of OSI-930 in Cancer Patients (NCT00513851) | Astellas Pharma Inc | 2006-04-01 |
| To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. (NCT00861419) | Amgen | 2005-12-01 |
| CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors (NCT00949624) | Arog Pharmaceuticals, Inc. | 2005-12-01 |
| A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available (NCT00785538) | Eli Lilly and Company | 2005-10-01 |
| Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer (NCT00207090) | R-Pharm | 2005-09-01 |
| A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function (NCT00139620) | OSI Pharmaceuticals | 2005-08-22 |
| Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas (NCT00955786) | Cylene Pharmaceuticals | 2005-07-01 |
| MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001) (NCT00099346) | Merck Sharp & Dohme LLC | 2005-01-01 |
| Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy (NCT00793975) | Eli Lilly and Company | 2005-01-01 |
| Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies (NCT00207129) | R-Pharm | 2004-10-01 |
| Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours (NCT00692354) | Chroma Therapeutics | 2004-10-01 |
| Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer (NCT00712504) | Pfizer | 2004-07-01 |
| Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors (NCT02225002) | Abramson Cancer Center at Penn Medicine | 2004-01-01 |
| Study of AS1411 in Advanced Solid Tumours (NCT00881244) | Antisoma Research | 2003-09-01 |
| Study of E7389 in Patients With Advanced Solid Tumors (NCT00069264) | Eisai Inc. | 2003-09-01 |
| Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors (NCT00116896) | OSI Pharmaceuticals | 2003-06-01 |
| First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors (NCT01469052) | Pfizer | 2002-11-01 |
| Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors (NCT06370013) | TransThera Sciences (Nanjing), Inc. | |
| Ixabepilone and Pemetrexed/Solid Tumors (NCT01170871) | University of Southern California | |